Drugs / L-lysine/L-arginine-containing Amino Acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07150806 Background | Nov 2025 → Dec 2026 expected | meningioma | Joshua Palmer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-lysine/L-arginine-containing Amino Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07150806 ↗ |
| Route | Intravenous | “Patients receive RYZ101 intravenously (IV) and amino acids, with L-arginine and L-lysine, IV on day 1 of each cycle.” NCT07150806 ↗ |